Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Circulatory shocks are responsible for one third of intensive care unit (ICU) admissions (20,000 patients per year in France) and are associated with 40% mortality [1,2]. Vascular hyperpermeability (also called vascular leakage) is a major feature of circulatory failure. During systemic inflammatory response syndrome (SIRS), massive vascular leakage affects macro and micro-circulation, and participates in the development of multiple organ failure [1,3]. Accordingly, fluid balance (the difference between fluid input and output) correlates independently with mortality during both septic and cardiogenic shock [4-7] and controlling capillary leakage was highly beneficial in numerous animal models of circulatory failure [8-10]. However, the determinants of vascular leakage remain poorly understood in humans.
The purpose of this study is to evaluate the link between circulatory levels of several proteins and the level of vascular leakage, in three distinct types of circulatory shocks.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with a circulatory failure | All patients hospitalized in ICU with a circulatory failure due to septic shock, cardiogenic shock, or post-resuscitation syndrome. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Fluid balance from Day 0 to day 3 | (ml/kg of initial body weight). The fluid balance, routinely monitored in ICU, represents fluid intakes (perfusion, oral intakes,..) - fluid losses (diuresis, diarrhea,…) | Between Day 0 and Day 3 |
| Measure | Description | Time Frame |
|---|---|---|
| Fluid balance | (ml/kg of initial body weight). The fluid balance, routinely monitored in ICU, represents fluid intakes (perfusion, oral intakes,..) - fluid losses (diuresis, diarrhea,…) | Day 1, Day 3, Day 7, Day 14 |
| Extra-vascular lung water index |
Not provided
Inclusion Criteria:
Informed consent from patient or a legal representative/family member/close relative. The patient will be asked to give his/her consent for the continuation of the trial when his/her condition will allow.
Affiliation to social security (AME excluded)
Patient with one of the circulatory failures described below:
septic shock
cardiogenic shock
post-resuscitation syndrome
Cardiogenic shock:
Post-resuscitation syndrome:
Septic shock:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients hospitalized in ICU with a circulatory failure due to septic shock, cardiogenic shock, or post-resuscitation syndrome.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nicolas BRECHOT, MD, PhD | Contact | +331 56 09 23 42 | nicolas.brechot@aphp.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Européen Georges Pompidou | Recruiting | Paris | 75015 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012770 | Shock, Cardiogenic |
| D000080942 | Post-Cardiac Arrest Syndrome |
| D012772 | Shock, Septic |
| ID | Term |
|---|---|
| D009203 | Myocardial Infarction |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Samples (serum and Ficoll-isolated cells), taken as part of the study will be stored in a biological sample collection (for patient who have given their consent).
Extra-vascular lung water index (EVLWi, ml/kg) and pulmonary vascular permeability index measured by transpulmonary thermodilution at corresponding time-points
| Day 0, Day 1, Day 3, Day 7, Day 14 |
| Serum albuminemia | g/L | Day 0, Day 1, Day 3, Day 7, Day 14 |
| Serum lactatemia | mmoles/L | Day 0, Day 1, Day 3, Day 7, Day 14 |
| Arterial PaO2 | (mmHg) | Day 0, Day 1, Day 3, Day 7, Day 14 |
| Circulating cytokine inflammatory profile IL-33 | (pg/ml) | Day 0, Day 1, Day 3, Day 7, Day 14 |
| Circulating cytokine inflammatory profile TNF-alpha | (pg/ml) | Day 0, Day 1, Day 3, Day 7, Day 14 |
| Circulating cytokine inflammatory profile IL-6 | (pg/ml) | Day 0, Day 1, Day 3, Day 7, Day 14 |
| Circulating cytokine inflammatory profile IL-1 | (pg/ml) | Day 0, Day 1, Day 3, Day 7, Day 14 |
| SOFA score | Association between circulating candidate proteins, the immune-inflammatory profile of the patients and SOFA score | Day 0, Day 1, Day 3, Day 7, Day 14 |
| Catecholamine-free days | Number of days alive without receiving any catecholamine | Day 0 to Day 7, Day 30 |
| Ventilatory-free days | Number of days alive without receiving any machenical ventilation, invasive or non-invasive | Day 0 to Day 7, Day 30 |
| Renal replacement therapy-free | Number of days alive without receiving any renal replacement therapy | Day 0 to Day 7, Day 30 |
| Mortality | Day 30 |
| D014652 |
| Vascular Diseases |
| D007238 | Infarction |
| D007511 | Ischemia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009336 | Necrosis |
| D012769 | Shock |
| D001930 | Brain Injuries |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D015427 | Reperfusion Injury |
| D011183 | Postoperative Complications |
| D018805 | Sepsis |
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |